Screening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients

Basit Öğe Kaydı
dc.contributor.authorCil, Timucin
dc.contributor.authorAltintas, Abdullah
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorPasa, Semir
dc.contributor.authorBayan, Kadim
dc.contributor.authorBatun, Sabri
dc.contributor.authorBuyukbayram, Huseyin
dc.date.accessioned2024-04-24T17:40:12Z
dc.date.available2024-04-24T17:40:12Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/aims: Celiac disease is an abnormal T cell-mediated immune response against dietary gluten in genetically predisposed individuals. The aim of our prospective study was to evaluate the frequency of Celiac disease in patients with lymphoma and to determine the usefulness of the anti-gliadin and anti-endomysial antibodies (EMA) for diagnosis of Celiac disease in this patient group. Methods: We studied 119 patients with previously or newly diagnosed non-Hodgkin's lymphoma and 60 patients with Hodgkin's lymphoma who presented at the hematology and medical oncology divisions of Dicle University Hospital in Turkey between December 2002 and January 2006. Serological screening for Celiac disease was performed in all patients by searching for serum anti-gliadin immanoglobulin A and immunoglobulin G, and EMA immunoglobulin A and immunoglobulin G. Results: In the Hodgkin's lymphoma group, anti-gliadin immunoglobulin A teas detected in 9 (15%) patients (3 male, 6 female), and anti-gliadin immunoglobulin G teas detected in 21 (35%) patients (15 male, 6 female). In the non-Hodgkin's lymphoma group, anti-gliadin immunoglobulin A teas detected in 6 (5%) patients (2 M male 4 female), and anti-gliadin immunoglobulin G was detected in 30 (25.2%) patients (18 male, 12 female). EMA immunoglobulin A and immunoglobulin G were not detected in the Hodgkin's lymphoma and non-Hodgkin's lymphoma groups. Conclusions: Our report is the first to describe the frequency of Celiac disease in patients with lymphoma in the southeast region of Turkey. In our study, there teas no evidence that Celiac disease is a pre-malignant condition for lymphoma. Serological screening for Celiac disease in lymphoma patients does not seem to be necessary.en_US
dc.identifier.endpage92en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue2en_US
dc.identifier.pmid19530040
dc.identifier.startpage87en_US
dc.identifier.urihttps://hdl.handle.net/11468/21670
dc.identifier.volume20en_US
dc.identifier.wosWOS:000283605700002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCeliac Diseaseen_US
dc.subjectAnti-Endomysium Antibodyen_US
dc.subjectAnti-Gliadin Antibodyen_US
dc.subjectLymphomaen_US
dc.titleScreening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patientsen_US
dc.titleScreening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu